Daiichi Sankyo brings Glycotope antibody in-house for $132.5M
Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope.
The one-off fee “satisfies” all milestone and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
